This review summarizes available and future options for reversing the effects of traditional and new oral anticoagulants to manage bleeding complications.
Answers are grounded in this paper and cite their sources.
Offers a synthesis of reversal strategies for oral anticoagulants; leaves open validation of emerging agents in prospective studies.
Anticoagulants are the mainstay of therapy for thromboembolic diseases. In addition to the more traditional agents, new oral anticoagulants, including dabigatran etexilate, rivaroxaban, and apixaban, have been shown to be effective across several indications. Bleeding is a serious complication associated with any anticoagulant, but many of the traditional parenteral and new oral agents do not currently have specific antidotes. This review describes available and future options for the reversal of the effects of anticoagulants, in particular the new oral agents and discusses current management strategies for bleeding events in clinical practice.
No takes yet. Share an insight, caveat, or question.
Kenneth A. Bauer (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: